nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
A diachronic-comparative analysis for the identification of the most powerful prognostic index for localized diffuse large B-cell lymphoma
|
Mian, M. |
|
|
25 |
12 |
p. 2398-2404 |
artikel |
2 |
Circulating tumor cells and circulating tumor DNA for precision medicine: dream or reality?
|
Ignatiadis, M. |
|
|
25 |
12 |
p. 2304-2313 |
artikel |
3 |
Cognitive function and fatigue after diagnosis of colorectal cancer
|
Vardy, J. |
|
|
25 |
12 |
p. 2404-2412 |
artikel |
4 |
Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials
|
Le Cesne, A. |
|
|
25 |
12 |
p. 2425-2432 |
artikel |
5 |
Editorial board
|
|
|
|
25 |
12 |
p. ii-iii |
artikel |
6 |
Effect of functional nuclear factor-kappaB genetic polymorphisms on hepatitis B virus persistence and their interactions with viral mutations on the risk of hepatocellular carcinoma
|
Zhang, Q. |
|
|
25 |
12 |
p. 2413-2419 |
artikel |
7 |
Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2 †
|
Piccart, M. |
|
|
25 |
12 |
p. 2357-2362 |
artikel |
8 |
Expression of E6AP and PML predicts for prostate cancer progression and cancer-specific death
|
Birch, S.E. |
|
|
25 |
12 |
p. 2392-2397 |
artikel |
9 |
Focal or combined modality for the management of brain metastasis: did high tech radiotherapy superseded drug-radiotherapy combination?
|
Deutsch, E. |
|
|
25 |
12 |
p. 2293-2294 |
artikel |
10 |
Glucocorticoid prescriptions and breast cancer recurrence: a Danish nationwide prospective cohort study
|
Lietzen, L.W. |
|
|
25 |
12 |
p. 2419-2425 |
artikel |
11 |
PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics
|
Massi, D. |
|
|
25 |
12 |
p. 2433-2442 |
artikel |
12 |
Pemetrexed versus gefitinib as a second-line treatment in advanced nonsquamous nonsmall-cell lung cancer patients harboring wild-type EGFR (CTONG0806): a multicenter randomized trial †
|
Zhou, Q. |
|
|
25 |
12 |
p. 2385-2391 |
artikel |
13 |
Prioritizing targets for precision cancer medicine
|
Andre, F. |
|
|
25 |
12 |
p. 2295-2303 |
artikel |
14 |
Prognostic value of CpG island methylator phenotype among colorectal cancer patients: a systematic review and meta-analysis
|
Juo, Y.Y. |
|
|
25 |
12 |
p. 2314-2327 |
artikel |
15 |
Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset
|
Blons, H. |
|
|
25 |
12 |
p. 2378-2385 |
artikel |
16 |
REBECA: a phase I study of bevacizumab and whole-brain radiation therapy for the treatment of brain metastasis from solid tumours
|
Lévy, C. |
|
|
25 |
12 |
p. 2351-2356 |
artikel |
17 |
Reply to the letter to the editor ‘Second-line chemotherapy in advanced biliary cancer: the present now will later be past’ by Vivaldi et al.
|
Lamarca, A. |
|
|
25 |
12 |
p. 2444-2445 |
artikel |
18 |
Second-line chemotherapy in advanced biliary cancer: a systematic review
|
Lamarca, A. |
|
|
25 |
12 |
p. 2328-2338 |
artikel |
19 |
Second-line chemotherapy in advanced biliary cancer: the present now will later be past
|
Vivaldi, C. |
|
|
25 |
12 |
p. 2443-2444 |
artikel |
20 |
SIE-SIES-GITMO Guidelines for the management of adult peripheral T- and NK-cell lymphomas, excluding mature T-cell leukaemias
|
Corradini, P. |
|
|
25 |
12 |
p. 2339-2350 |
artikel |
21 |
Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44–GeparQuinto) †
|
von Minckwitz, G. |
|
|
25 |
12 |
p. 2363-2372 |
artikel |
22 |
Table of Contents
|
|
|
|
25 |
12 |
p. iv-v |
artikel |
23 |
The performance of BRCA1 immunohistochemistry for detecting germline, somatic, and epigenetic BRCA1 loss in high-grade serous ovarian cancer
|
Meisel, J.L. |
|
|
25 |
12 |
p. 2372-2378 |
artikel |